The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.

Allogene Therapeutics, a US-based cancer drug developer that counts Pfizer and Gilead Sciences among its investors, raised $324m in an initial public offering on the Nasdaq Global Select Market yesterday. The offering consisted of 18 million shares priced at $18.00 each, at the top of its $16 to $18 range, giving Allogene a market capitalisation…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.